UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine (FFA) in children and adults with CDKL5 ...
This week’s ThreatsDay Bulletin covers USB malware, fake crypto scams, CastleRAT, new cyber laws, and falling ransomware ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback